RTI Surgical Inc. (NASDAQ:RTIX) shares rose 6.1% on Monday . The company traded as high as $3.32 and last traded at $3.30, with a volume of 93,185 shares changing hands. The stock had previously closed at $3.11.

RTIX has been the topic of a number of recent research reports. Zacks Investment Research raised shares of RTI Surgical from a “hold” rating to a “strong-buy” rating and set a $4.75 price target on the stock in a research report on Wednesday, April 20th. Craig Hallum cut shares of RTI Surgical from a “buy” rating to a “hold” rating and reduced their price target for the company from $6.00 to $4.00 in a research report on Thursday, July 28th.

The company has a 50-day moving average price of $3.51 and a 200-day moving average price of $3.69. The stock has a market cap of $191.23 million and a price-to-earnings ratio of 46.62.

RTI Surgical (NASDAQ:RTIX) last posted its quarterly earnings data on Wednesday, July 27th. The company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of $0.03 by $0.08. The business had revenue of $67.60 million for the quarter, compared to the consensus estimate of $66.52 million. The company’s quarterly revenue was down 5.6% on a year-over-year basis. During the same period in the previous year, the company earned $0.04 earnings per share. Equities analysts anticipate that RTI Surgical Inc. will post $0.10 EPS for the current year.

A hedge fund recently raised its stake in RTI Surgical stock. Royce & Associates LLC boosted its position in shares of RTI Surgical Inc. (NASDAQ:RTIX) by 30.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,558,774 shares of the company’s stock after buying an additional 368,000 shares during the period. Royce & Associates LLC owned approximately 2.71% of RTI Surgical worth $6,188,000 as of its most recent SEC filing.

RTI Surgical, Inc is engaged in producing orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues. The Company uses natural tissues, metals and synthetics process to produce its products. The Company’s business primarily consists of six categories, such as spine, sports medicine, ortho fixation, bone graft substitutes and general orthopedic (BGS and general orthopedic), dental and surgical specialties.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.